{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03484741",
      "OrgStudyIdInfo": {
        "OrgStudyId": "DIME 1001"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "DIME 1001",
            "SecondaryIdType": "Other Identifier",
            "SecondaryIdDomain": "Ministry of Health, Viet Nam"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "Van Hanh General Hospital",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Mesenchymal Stem Cell Therapy for Type 1 Diabetes Mellitus Patients",
      "OfficialTitle": "A Preliminary Safety and Efficacy Evaluation of Mesenchymal Stem Cell Transplantation for Type 1 Diabetes Mellitus (T1DM) Patients"
    },
    "StatusModule": {
      "StatusVerifiedDate": "April 2018",
      "OverallStatus": "Unknown status",
      "LastKnownStatus": "Recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "April 1, 2017",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "November 2018",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "November 2018",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "March 16, 2018",
      "StudyFirstSubmitQCDate": "March 25, 2018",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "April 2, 2018",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "April 2, 2018",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "April 4, 2018",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Van Hanh General Hospital",
        "LeadSponsorClass": "OTHER"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "University of Science Ho Chi Minh City",
            "CollaboratorClass": "OTHER"
          }
        ]
      }
    },
    "OversightModule": {
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells (MSCs) transplantation for type 1 Diabetes Mellitus patients.",
      "DetailedDescription": "Mesenchymal stem cells (MSCs) are collected from autologous bone marrow mononuclear cells and allogeneic umbilical cord tissue (UC-MSC).\n\n15 patients with type 1 Diabetes Mellitus will be enrolled and will receive MSCs by intravenous infusion. They were followed up for 6 months after transplantation.\n\nSafety is to assess the occurrence of adverse events (AEs) during either stem cells infusion or by physician assessments.\n\nThe primary endpoint is to assess the improvement of patients' Fasting blood glucose, HbA1C, C-peptide, and blood insulin level."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Type 1 Diabetes Mellitus"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "15",
        "EnrollmentType": "Anticipated"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "MSC and PRP",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "15 patients will be given autologous bone marrow-derived mesenchymal stem cells (BM-MSC) and mesenchymal stem cell from allogeneic umbilical cord tissue (UC-MSC) combined with platelet-rich plasma (PRP) by intravenous infusion.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: MSC and PRP"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "MSC and PRP",
            "InterventionDescription": "MSC are collected from autologous bone marrow mononuclear cells (BMNC) and allogeneic umbilical cord tissue (UC-MSC) under sterile conditions and combined with activated platelet-rich plasma (PRP) to treat this disease.",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "MSC and PRP"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Fasting blood glucose",
            "PrimaryOutcomeDescription": "Assess the changes in fasting blood glucose level after transplantation",
            "PrimaryOutcomeTimeFrame": "every month in the course of 6 months"
          },
          {
            "PrimaryOutcomeMeasure": "Hemoglobin A1c (HbA1c) level",
            "PrimaryOutcomeDescription": "Assess the changes in HbA1C level after transplantation",
            "PrimaryOutcomeTimeFrame": "1 month, 3 months and 6 months after transplantation"
          },
          {
            "PrimaryOutcomeMeasure": "Adverse events",
            "PrimaryOutcomeDescription": "Evaluate the safety of therapy by number record of adverse events (AEs)",
            "PrimaryOutcomeTimeFrame": "during the course of 6 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Insulin dose",
            "SecondaryOutcomeDescription": "Reduction of insulin dose after transplantation",
            "SecondaryOutcomeTimeFrame": "during the course of 6 months"
          },
          {
            "SecondaryOutcomeMeasure": "C-peptide",
            "SecondaryOutcomeDescription": "Assess the improvement in C-peptide level after transplantation",
            "SecondaryOutcomeTimeFrame": "every month in the course of 6 months"
          },
          {
            "SecondaryOutcomeMeasure": "Blood insulin level",
            "SecondaryOutcomeDescription": "Assess the changes in blood insulin level after transplantation",
            "SecondaryOutcomeTimeFrame": "every month in the course of 6 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nWho is diagnosed with Type 1 Diabetes Mellitus according to the ADA, the patients meet at least one of the following criteria:\n\nAt least one autoantibody associated with Type 1 Diabetes Mellitus such as ICA or GAD.\nPreviously diagnosed at a medical facility with Type 1 Diabetes.\nHaving evidence of insulin depletion based on the test results during screening.\nPatients treated with fixed insulin dose for at least 3 months.\nMales and females between age 18 and 45 years at the screening.\nPatients able to read, write and understand ICF form\n\nExclusion Criteria:\n\nUncontrolled blood pressure at the time of enrollment: systolic pressure >160 mmHg and/or diastolic blood pressure > 100 mmHg.\n\nHaving evidence related to renal dysfunction:\n\ncreatinine > 1.5 mg/dl or (>133 mmol/L) for men.\ncreatinine > 1.4 mg/dl or (>124 mmol/L) for woman.\neGRF < 40 ml/ min\nProteinuria > 300 mg/day\nHaving evidence of ketoacidosis at the time of selection.\nHaving evidence of ongoing or frequent hypoglycemia.\nHaving severe infection\nInfected with hepatitis B virus or hepatitis C or tuberculosis. Positive results of HbsAg or Anti HCV or/and PCR tuberculosis are only acceptable in case of vaccination and without suspicious signs. All other cases are not accepted even in the absence of clinical signs.\nDiseases detected before/during screening such as cardiovascular disease, respiratory disease ( pulmonary, fibrosis, chronic respiratory failure), liver disease, cancer, neurology, metabolism.\nHaving abnormalities in red blood cells such as sickle cells disease.\nUsing alcohol and/or tobacco.\nBlood clotting disorders (INR > 1.5, PTT >40, PT > 15).\nTaking any anticoagulant.\nTaking systemic steroids.\nParticipate in another clinical study involving experimenting drugs and/or medical equipment.\nPatients who are unable to perform the tests and assessments needed for the study (eg, patients who are unable to perform bone marrow transplantation) or patients who do not agree to participate in the study.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "45 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "CentralContactList": {
        "CentralContact": [
          {
            "CentralContactName": "Phuong Le, MSc-MD",
            "CentralContactRole": "Contact",
            "CentralContactPhone": "(+84)902742732",
            "CentralContactEMail": "drbphuong@gmail.com"
          },
          {
            "CentralContactName": "Stem Cell Unit, Van Hanh General Hospital",
            "CentralContactRole": "Contact",
            "CentralContactEMail": "tebaogocvanhanh@gmail.com"
          }
        ]
      },
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Phuong Le, MSc-MD",
            "OverallOfficialAffiliation": "Stem Cell Unit, Van Hanh General Hospital",
            "OverallOfficialRole": "Principal Investigator"
          },
          {
            "OverallOfficialName": "Ngoc Phan, MSc",
            "OverallOfficialAffiliation": "Stem Cell Institute, University of Science Ho Chi Minh City",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Van Hanh Geral Hospital",
            "LocationStatus": "Recruiting",
            "LocationCity": "Ho Chi Minh City",
            "LocationState": "Ho Chi Minh",
            "LocationZip": "700000",
            "LocationCountry": "Vietnam",
            "LocationContactList": {
              "LocationContact": [
                {
                  "LocationContactName": "Phuong Le, MSc-MD",
                  "LocationContactRole": "Contact",
                  "LocationContactPhone": "(+84)902742732",
                  "LocationContactEMail": "drbphuong@gmail.com"
                }
              ]
            }
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "Yes",
      "IPDSharingInfoTypeList": {
        "IPDSharingInfoType": [
          "Study Protocol",
          "Clinical Study Report (CSR)"
        ]
      },
      "IPDSharingTimeFrame": "6 months after publication",
      "IPDSharingAccessCriteria": "Type 1 Diabetes Mellitus"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000003920",
            "ConditionMeshTerm": "Diabetes Mellitus"
          },
          {
            "ConditionMeshId": "D000003922",
            "ConditionMeshTerm": "Diabetes Mellitus, Type 1"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000044882",
            "ConditionAncestorTerm": "Glucose Metabolism Disorders"
          },
          {
            "ConditionAncestorId": "D000008659",
            "ConditionAncestorTerm": "Metabolic Diseases"
          },
          {
            "ConditionAncestorId": "D000004700",
            "ConditionAncestorTerm": "Endocrine System Diseases"
          },
          {
            "ConditionAncestorId": "D000001327",
            "ConditionAncestorTerm": "Autoimmune Diseases"
          },
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M6267",
            "ConditionBrowseLeafName": "Diabetes Mellitus",
            "ConditionBrowseLeafAsFound": "Diabetes Mellitus",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M6269",
            "ConditionBrowseLeafName": "Diabetes Mellitus, Type 1",
            "ConditionBrowseLeafAsFound": "Type 1 Diabetes Mellitus",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M10791",
            "ConditionBrowseLeafName": "Metabolic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M24556",
            "ConditionBrowseLeafName": "Glucose Metabolism Disorders",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M7014",
            "ConditionBrowseLeafName": "Endocrine System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M3781",
            "ConditionBrowseLeafName": "Autoimmune Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC18",
            "ConditionBrowseBranchName": "Nutritional and Metabolic Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC19",
            "ConditionBrowseBranchName": "Gland and Hormone Related Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          }
        ]
      }
    }
  }
}